Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-05-21 AGM Information
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document is titled "Mauna Kea Technologies annonce la mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 6 juin 2024 et précise les modalités de participation". This explicitly states that the preparatory documents for the Annual General Meeting (AGM) are being made available and details the voting procedures. This content directly relates to the materials and announcements surrounding the AGM. The most specific category for AGM-related materials and presentations is 'AGM Information' (AGM-R). Although it announces the availability of documents (which could suggest RPA), the core subject matter is the AGM itself, making AGM-R the primary classification. The document is not the full proxy statement (DEF 14A) or the voting results (DVA), but the announcement and details regarding the meeting where voting occurs.
2024-05-21 French
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 98% confidence The document explicitly announces the availability of preparatory documents for the 'Combined General Meeting of June 6, 2024' and details the instructions for participation and voting. Key phrases include 'announces the availability of preparatory documents for the Combined General Meeting' and details on voting procedures (mail, proxy, in person). This content directly relates to the materials and announcements surrounding an Annual General Meeting (AGM). Although it announces documents, the core subject matter is the AGM itself, making 'AGM Information' (AGM-R) the most appropriate classification over a general 'Report Publication Announcement' (RPA), as it focuses specifically on the meeting logistics and associated materials rather than just the publication of a standard financial report.
2024-05-21 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital) and explicitly references Article L233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares outstanding and the total gross and net voting rights as of a specific date (April 30, 2024), announced on May 17, 2024. This type of mandatory disclosure in France regarding the total voting rights is a specific regulatory filing. While it relates to capital structure, it is not a general financing announcement (CAP) or a share issue/repurchase report (SHA/POS). It is a specific regulatory disclosure about voting rights, which fits best under the general regulatory filing category (RNS) or, more specifically, a declaration related to voting rights/capital structure. Given the options, this is a mandatory regulatory disclosure concerning voting rights, which is often grouped with other mandatory notifications. Since there isn't a specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory announcement, RNS (Regulatory Filings) is the most appropriate fallback, although DVA (Declaration of Voting Results) is related to voting, this document reports the *total potential* voting rights, not the *results* of a vote. However, looking closely at the definitions, DVA is for 'Official results from shareholder votes at any general meeting'. This document is a periodic disclosure of the total voting power base. In many jurisdictions, this falls under general regulatory reporting. Given the French regulatory context (AMF reference), RNS is the safest general regulatory classification if a more specific one isn't available. Upon re-evaluation, this document is a mandatory disclosure of the total number of voting rights, which is a key component of shareholder structure reporting. It is not a declaration of voting *results* (DVA). It is a regulatory filing. I will classify it as RNS.
2024-05-17 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Monthly information regarding the total number of voting rights and shares comprising the share capital' and provides a table detailing the number of shares and voting rights as of April 30, 2024. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement, often related to major shareholding notifications or general capital structure updates. Reviewing the definitions, this content most closely aligns with reporting changes in significant share ownership or capital structure details. Since it is a monthly update on the total number of shares and voting rights, it fits best under Major Shareholding Notification (MRQ) as it directly relates to the denominator used for calculating ownership thresholds, or potentially a specific type of Regulatory Filing (RNS) if MRQ is too narrow. However, given the explicit focus on the total number of voting rights and shares, which is a key component of major shareholding disclosures, MRQ is the most precise fit among the provided options, although it is not strictly a notification of a *change* by a specific shareholder, but rather a mandatory disclosure of the total base figure. Since it is a mandatory, periodic disclosure related to capital structure and voting rights, and not a general earnings release, management discussion, or audit report, and it is not a proxy statement or dividend notice, MRQ (Major Shareholding Notification) is the closest fit for capital structure transparency filings that aren't 10-K/IR. If MRQ is interpreted strictly as a notification *by* a shareholder crossing a threshold, then RNS (Regulatory Filings) would be the fallback. Given the context of mandatory monthly disclosure of voting rights, it is a specific regulatory filing. Let's re-evaluate the options: It is not a DVA (Voting Results), not a DIV (Dividend), not a SHA (Share Issue). It is a periodic disclosure of capital structure metrics. In many jurisdictions, these monthly voting rights disclosures are filed under general regulatory announcements. Given the specific nature of the data (total voting rights), and lacking a dedicated 'Share Capital Disclosure' code, RNS is the safest fallback for a mandatory, non-standard report, but MRQ is highly relevant to the content. I will select RNS as the most appropriate general regulatory filing category for this specific monthly capital structure disclosure that doesn't fit the other specific codes perfectly, as it is a regulatory announcement.
2024-05-17 English
Inside Information / Other news releases
Environmental & Social Information Classification · 99% confidence The document is a press release dated May 6, 2024, announcing that Mauna Kea Technologies will present 9 abstracts related to its Cellvizio platform at the Digestive Disease Week® (DDW) Conference. It details the titles, times, and presenters for these scientific presentations. This type of announcement, focusing on participation in a scientific or industry conference and highlighting research findings, is best classified as an Investor Presentation (IP) or a general announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a management discussion (MDA), and it is specifically detailing scientific data presentations intended for investors and the medical community, 'Investor Presentation' (IP) is the most fitting category, as these announcements often accompany or precede investor-focused materials. It is not a report itself, but an announcement about scientific data being presented, which aligns closely with the scope of investor communications.
2024-05-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 6, 2024, announcing that Mauna Kea Technologies will have 9 presentations regarding its Cellvizio product at the Digestive Disease Week® (DDW) conference in May 2024. It details the topics of the presentations and includes quotes from the CEO. It also references recent financial results (FY 2023 and Q1 2024) and contains a standard forward-looking statements disclaimer referencing the 2023 Annual Report filed on April 30, 2024. This document is an announcement about scientific/clinical data being presented at a major industry conference, not a formal regulatory financial filing (like 10-K, IR, or ER). It is a general corporate update focused on clinical validation and upcoming events. Since it is not a specific financial report, management discussion, or a formal regulatory filing like a 10-K or ER, the most appropriate category is a general Regulatory Filing (RNS) as a catch-all for significant corporate news that doesn't fit the other specific categories, although it functions similarly to an Investor Presentation (IP) in terms of content focus, it is structured as a press release announcing external presentations. Given the options, RNS is the best fit for a non-standard, material corporate announcement.
2024-05-06 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.